Latest News

Carrier Advisory Committee Seeks Physician Expertise on Draft Coverage Determinations

Posted 6/06/19 (Thu)

Noridian maintains a Carrier Advisory Committee (CAC) in each state to serve as a formal mechanism for physicians to be informed of and participate in the development of a Local Coverage Determination (LCD) in an advisory capacity.

The Montana/North Dakota/Wyoming Carrier Advisory Committee, chaired by William Noyes, MD of Grand Forks, held a meeting in June and was attended by NDMA Executive Director Courtney Koebele.

As a result, CAC is seeking PHYSICIAN COMMENTS on the following LCDs NO LATER THAN JULY 15, 2019.

Click on the link to learn more; then forward your comments to Ms. Koebele at ckoebele@ndmed.com, OR contact via phone: 701-223-9475.

A. Lab: Drug Interaction Testing

B. MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with UnfavorableIntermediate Risk Disease

C. MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Favorable IntermediateRisk Disease

D. MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Solid Tumors

E. MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies andSuspected Myeloid Malignancies

F. MolDX: Next-Generation Sequencing for Solid Tumors

G. MolDX: Pigmented Lesion Assay

H. MolDX: Prospera

I. MolDX: TruGraf Blood Gene Expression Test

Comments are greatly appreciated so any issues can be addressed before the policy finalizes.
NDMA Executive Director Courtney Koebele.

Carrier Advisory Committee Seeks Physician Expertise on Draft Coverage Determinations

Sorry no Tweets at this time